Page 2 - Lancet Report

1 in 8 Covid-19 patients develop long-term symptoms: Lancet study

in eight adults who are infected with SARS-CoV-2 experience long term symptoms due to Covid-19, according to one of the most comprehensive studies on the viral disease to date.

One in 8 SARS-CoV-2 patients develop long Covid symptoms: Lancet study

One in eight adults who are infected with the SARS-CoV-2 virus experience long term symptoms due to COVID-19, according to a large Dutch study published on Friday in The Lancet journal

Nasal spray lowers Covid viral load by 94% in 24 hours, reveals Lancet

A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours

Covid-19 vaccine protects people of all body weights: Lancet study

Vaccine effectiveness was similar for those with a higher body mass index (BMI) and of a healthy weight, but slightly lower in the underweight group

Long Covid in infected children can last at least two months: Lancet study

Children infected with the SARS-CoV-2 virus can experience symptoms of long COVID lasting at least two months, according to a study published in The Lancet Child & Adolescent Health journal on Thursday. The largest study to date of long COVID symptoms in children aged 0-14 years used national level sampling of children in Denmark and matched COVID-19 positive cases with a control group with no prior history of a the disease. "The overall aim of our study was to determine the prevalence of long-lasting symptoms in children and infants, alongside quality of life, and absence from school or day care," said Professor Selina Kikkenborg Berg, from Copenhagen University Hospital, Denmark "Our results reveal that, although children with a positive COVID-19 diagnosis are more likely to experience long-lasting symptoms than children with no previous COVID-19 diagnosis, the pandemic has affected every aspect of all young people's lives," Berg said. Further research into the long-term ...

Unlike Delta variant, Omicron less likely to cause long Covid: Lancet study

The Omicron variant of the SARS-CoV-2 virus is less likely to cause long COVID than the Delta strain, according to a study published in The Lancet journal. Long COVID is defined as having new or ongoing symptoms four weeks or more after the start of the disease, the researchers said. Symptoms include fatigue, shortness of breath, loss of concentration, and joint pain, which can adversely affect day-to-day activities, and in some cases can be severely limiting, they said. The researchers found that the odds of experiencing long COVID were between 20-50 per cent less during the Omicron period versus the Delta period, depending on age and time since vaccination. "The Omicron variant appears substantially less likely to cause Long-COVID than previous variants but still 1 in 23 people who catch COVID-19 go on to have symptoms for more than four weeks," said study lead author Claire Steves from King's College London, UK. The study identified 56,003 UK adult cases first testing positive

Bharat Biotech's Covaxin is safe for children between 2 and 18 yrs: Lancet

Data from over 50 million doses reveals minimal side effects

Some antivirals may be effective against Monkeypox virus: Lancet

A team of researchers have found that some antiviral medications might have the potential to shorten symptoms and reduce the amount of time a patient is contagious with Monkeypox virus.

Siga Tech's tecovirimat drug could help counter monkeypox, says study

The scientists said more work is needed to reach any conclusions but their study found little evidence that another drug, brincidofovir, was beneficial

Antiviral drugs could reduce monkeypox symptoms, says Lancet study

The research also reported the patient response to the first off-label use of two different antiviral medications -- brincidofovir and tecovirimat -- to treat the disease

Lancet publishes phase-3 trial data of Zydus' Covid vaccine ZyCoV-D

According to Zydus, the plug-and-play technology of the vaccine equips it to adapt to the rapidly mutating SARS COV-2 virus.

'Speculative, misinformed': Govt on Lancet's report on high Covid mortality

The Lancet reported on Thursday that the country accounted for around 22.3 per cent of global excess deaths as of December 31, 2021

Covid vax effectiveness declines after 6 months without boosters: Study

The study indicated that vaccines were 94 per cent effective at preventing hospitalisation 50-100 days after receiving the shot but fell to 80.4 per cent 200-250 days later

Booster gives antibody protection against Omicron variant: Lancet

Overall, antibody levels were nearly 2.5 times higher against Omicron after three doses compared to after two jabs

Booster dose provides good antibody protection against Omicron: Lancet

A third 'booster' dose of Covid-19 vaccine successfully raises antibody levels that neutralise the Omicron variant, according to laboratory findings.

Bharat Biotech updates Covaxin efficacy to 65.2% against Delta variant

Experts say more real-world studies are required now

Bharat Biotech's Covid-19 vaccine Covaxin gets mixed review from Lancet

Extrapolating from the report, Lancet said 'two doses offer 77.8 per cent protection against symptomatic Covid-19'.

Covid-19 can be transmitted by fully vaccinated people at home: Lancet

The study enrolled 621 participants, identified by the UK contact tracing system, between September 2020 and September 2021.

Antidepressant fluvoxamine may reduce risk of Covid-19 hospitalisation

Researchers treated 739 randomly selected Brazilian COVID-19 patients with fluvoxamine, with another 733 receiving a placebo, between January 15 to August 6 of this year.

Future health depends on radical change in digital technologies: Report

Digital technologies are transforming all areas of life and health, a trend that has been accelerated by the Covid-19 pandemic, but the benefits of these advances are not reaching everyone equally.